Clinical Trial Update: S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial (S1403) evaluated afatinib with or without cetuximab for newly diagnosed stage IV or recurrent EGFR-mutant non-small cell lung cancer; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERBITUX (cetuximab)
• Gilotrif (Afatinib)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-03-17